DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Apixaban is a drug marketed by Accord Hlthcare, Bionpharma Inc, Indoco, Micro Labs, and Mylan. and is included in five NDAs.
The generic ingredient in APIXABAN is apixaban. There are thirty drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the apixaban profile page.
A generic version of APIXABAN was approved as apixaban by ACCORD HLTHCARE on July 28th, 2020.
Summary for APIXABAN
Recent Clinical Trials for APIXABAN
Identify potential brand extensions & 505(b)(2) entrants
|Korea University Guro Hospital||Phase 2|
|The University of Cambridge (joint Sponsor)||Phase 3|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Accord Hlthcare||APIXABAN||apixaban||TABLET;ORAL||210180-001||Jul 28, 2020||AB||RX||No||No||Get Started for $10||Get Started for $10||Get Started for $10|
|Micro Labs||APIXABAN||apixaban||TABLET;ORAL||210013-001||Dec 23, 2019||DISCN||No||No||Get Started for $10||Get Started for $10||Get Started for $10|
|Bionpharma Inc||APIXABAN||apixaban||TABLET;ORAL||210152-002||Apr 8, 2020||DISCN||No||No||Get Started for $10||Get Started for $10||Get Started for $10|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|